VOX

DRUG7 trials

Sponsors

Gilead Sciences, Scentech Medical Technologies Ltd

Conditions

COVID-19Chronic Hepatitis CColorectal CancerHCV InfectionHepatitis C Virus InfectionInfectious DiseasePancreatic Cancer

Phase 1

Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol

CompletedNCT02533427

Gilead SciencesHCV Infection

Start: 2015-10-29End: 2016-03-18Updated: 2020-09-02

Phase 2

Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection

CompletedNCT02202980

Gilead SciencesChronic Hepatitis C

Start: 2014-08-04End: 2016-05-09Updated: 2018-11-16

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection

CompletedNCT02378935

Gilead SciencesHepatitis C Virus Infection

Start: 2015-02-17End: 2016-04-12Updated: 2020-03-06

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection

CompletedNCT02378961

Gilead SciencesHepatitis C Virus Infection

Start: 2015-02-16End: 2016-01-26Updated: 2020-03-03

Unknown Phase

Detection of COVID-19 Using Breath Analysis - Validation Study.

CompletedNCT05224622

Scentech Medical Technologies LtdCOVID-19

Start: 2022-01-18End: 2023-01-18Updated: 2023-05-31

Chemical Profiling of Colorectal and Pancreatic Cancers Using Breath Analysis - Feasibility Study

Not yet recruitingNCT05400408

Scentech Medical Technologies LtdColorectal Cancer, Pancreatic Cancer

Start: 2024-05-01End: 2025-03-31Target: 250Updated: 2024-02-07

Detection of Bacterial and Viral Pathogens Infection Among Hospitalized Patients Feasibility Study

WithdrawnNCT05399615

Scentech Medical Technologies LtdInfectious Disease

Start: 2022-12-30End: 2023-07-31Updated: 2023-05-16

Related Papers

Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.

2017-01-2734 citations

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.

2016-07-3050 citations

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.

2016-07-3036 citations

Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.

2016-05-2751 citations